HCAT
BEARISH
$1.0
Live
Health Catalyst, Inc. · NASDAQ
Target $1.96
(+97.2%)
$0.95
52W Range
$5.06
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
90%
HCAT exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 98%. While the stock appears cheap on a Price-to-Book (0.29) and Price-to-Sales (0.24) basis, these are 'value traps' given the negative revenue growth (-6.20%) and a massive collapse in YoY EPS (-3300%). The technical trend is completely bearish (0/100), and insider activity is negative, suggesting a lack of confidence from company leadership.
Key Strengths
Extremely low Price-to-Book ratio (0.29)
Low Price-to-Sales ratio (0.24)
Healthy short-term liquidity with a Current Ratio of 1.89
Strong Gross Margin of 49.70%
Low Forward P/E (6.29) if profitability targets are achieved
Key Risks
Severe financial health deterioration (Piotroski F-Score 2/9)
Negative revenue growth (-6.20% YoY and Q/Q)
Extreme earnings volatility and recent massive EPS miss (-843.2% surprise)
Strong bearish technical momentum with a 74% 1-year price drop
Insider selling by General Counsel and Director
AI Fair Value Estimate
Based on comprehensive analysis
$0.85
-14.7% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare HCAT against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning HCAT from our newsroom.
Newest → oldest
No matching news yet.